Caribou Biosciences, Inc. is a clinical-stage biopharmaceutical company using CRISPR gene-editing technology to transform cell therapies. It functions primarily in the US, dedicating its resources to making a significant impact in the lives of patients in need of new therapeutic solutions.
Positioned in the ever-evolving biotechnology industry, Caribou Biosciences has a commitment to discovering and developing novel CRISPR-Cas gene-edited cell therapies. The company operates independently with significant partnerships with AbbVie and equity investment from Pfizer.
Track the share price of CRBU by adding it to your eToro watchlist.